Does Affinity Health Plan Cover Vyvanse?

Understanding Affinity Health Plan and Its Current Status

Affinity Health Plan was a nonprofit Medicaid managed care organization serving members primarily in the New York City metropolitan area. In 2014, Molina Healthcare acquired Affinity Health Plan, and member plans transitioned to Molina Healthcare of New York [1]. If you currently hold a plan that was originally through Affinity, your coverage is now administered by Molina.

This matters because formulary decisions, prior authorization criteria, and preferred drug lists are maintained by Molina Healthcare of New York, not by the former Affinity Health Plan entity. Molina's Medicaid managed care formulary follows New York State Department of Health preferred drug list guidelines, with some plan-specific additions or restrictions [2]. Any inquiry about drug coverage should be directed to Molina's member services line or online portal rather than referencing older Affinity materials.

Molina Healthcare of New York serves Medicaid, Medicare-Medicaid (dual-eligible), and Marketplace enrollees. The formulary rules differ across these product lines. A Medicaid enrollee faces different step-therapy requirements than a Marketplace enrollee, even within the same parent company.

What Vyvanse Is and Why Coverage Questions Arise

Vyvanse (lisdexamfetamine dimesylate) is a prodrug stimulant. The body converts lisdexamfetamine into dextroamphetamine after oral ingestion, producing a smoother pharmacokinetic profile than immediate-release amphetamine formulations [3]. The FDA approved Vyvanse for attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 and older in 2007, and added an indication for moderate-to-severe binge eating disorder (BED) in adults in 2015 [4].

Coverage questions come up frequently because Vyvanse carried brand-only pricing for over 15 years. Takeda held patent protection until 2023, and the average wholesale price exceeded $400 per month for the brand product. Generic lisdexamfetamine capsules entered the U.S. market in August 2023, which lowered costs substantially but did not eliminate prior authorization requirements on most Medicaid managed care formularies [5].

In a key trial of lisdexamfetamine for adult ADHD (N=420), the drug produced a mean reduction of 15.9 points on the ADHD-RS-IV total score versus 6.2 points for placebo at the optimized dose (P<0.001) [6]. For BED, a 12-week trial (N=514) demonstrated a mean reduction of 3.87 binge days per week with lisdexamfetamine 50 or 70 mg versus 2.51 days with placebo [7].

Formulary Placement and Prior Authorization

On most New York Medicaid managed care formularies, including Molina's, stimulant medications follow a step-therapy protocol. Generic methylphenidate products (both immediate-release and extended-release) and generic mixed amphetamine salts sit on the preferred tier. Vyvanse, even in its generic lisdexamfetamine form, is frequently placed on a non-preferred tier.

Prior authorization for lisdexamfetamine on a Medicaid managed care plan typically requires documentation of the following: a confirmed diagnosis of ADHD or BED by a qualified clinician, an adequate trial (usually 4 to 6 weeks at therapeutic doses) of at least one preferred generic stimulant, and a clinical rationale for why the preferred agent was inadequate or not tolerated [2]. Some plans accept documented adverse effects such as rebound symptoms, appetite suppression severe enough to cause weight loss exceeding 5% of body weight, or cardiovascular side effects as valid reasons for step-therapy exceptions.

The turnaround for prior authorization decisions under New York Medicaid regulations is 24 hours for urgent requests and 3 business days for standard requests. If denied, members have the right to request a fair hearing through the New York State Office of Temporary and Disability Assistance.

"Prior authorization exists to ensure that patients try well-studied, cost-effective options first, but it should never be a barrier to medically necessary care," according to the American Academy of Family Physicians clinical guidance on ADHD pharmacotherapy [8].

How to Check Your Specific Coverage

The most direct route is calling the number on the back of your Molina member ID card. Ask the representative to confirm three things: whether lisdexamfetamine (generic or brand Vyvanse) is on your plan's formulary, what tier it occupies, and what prior authorization criteria apply.

You can also check online. Molina Healthcare of New York maintains a searchable formulary on its member portal. Select your specific plan type (Medicaid, Medicare-Medicaid, or Marketplace), then search for "lisdexamfetamine" or "Vyvanse." The result will show the tier, any quantity limits, and whether prior authorization or step therapy is required.

Pharmacy-level verification works too. Your pharmacist can run a test claim through the system before filling the prescription. This real-time adjudication check returns the plan's response within seconds and reveals any coverage blocks.

If you are a prescribing clinician, electronic prior authorization (ePA) through platforms like CoverMyMeds or Surescripts can simplify the process. A 2022 analysis published in the Journal of Managed Care & Specialty Pharmacy found that ePA reduced stimulant prior authorization processing time by 62% compared to fax-based submissions [9].

Brand Vyvanse vs. Generic Lisdexamfetamine

Since August 2023, multiple manufacturers have released generic lisdexamfetamine capsules. The FDA's Orange Book confirms therapeutic equivalence (AB rating) between generic lisdexamfetamine dimesylate capsules and brand Vyvanse [10]. This means the generic must deliver the same active metabolite (dextroamphetamine) at the same rate and extent as the brand.

Cost differences are significant. Brand Vyvanse carries an average wholesale price above $400 for a 30-day supply. Generic lisdexamfetamine costs approximately $30 to $80 for a 30-day supply at many pharmacies, though Medicaid copays are capped by federal law at $0 to $3.70 for most beneficiaries regardless of whether brand or generic is dispensed [11].

For Molina Medicaid members, the generic is almost always substituted automatically unless the prescriber writes "dispense as written" (DAW) with a valid clinical justification. If your pharmacy dispenses the generic, your out-of-pocket cost on Medicaid should be minimal.

On Molina Marketplace plans, the cost difference between brand and generic is larger at the point of sale. Brand Vyvanse on a non-preferred tier could carry a copay of $60 to $90 or more. Generic lisdexamfetamine on a preferred brand or generic tier might cost $15 to $35.

Alternatives if Coverage Is Denied

If your plan denies lisdexamfetamine coverage even after prior authorization, several clinically supported alternatives exist. These are not identical to Vyvanse, but each has a strong evidence base for ADHD.

Generic mixed amphetamine salts extended-release (the generic form of Adderall XR) shares the same active metabolite class and is typically on the preferred tier. A head-to-head crossover study (N=52) found comparable efficacy between lisdexamfetamine and mixed amphetamine salts XR, with slightly fewer rebound effects reported with lisdexamfetamine in the afternoon hours [12].

Generic methylphenidate extended-release products (such as generic Concerta or other OROS methylphenidate formulations) represent a different mechanism. Methylphenidate blocks dopamine and norepinephrine reuptake without releasing stored catecholamines. The NIMH Multimodal Treatment Study of ADHD (MTA, N=579) established methylphenidate as a first-line ADHD treatment over two decades ago [13].

For binge eating disorder specifically, if lisdexamfetamine is denied, the only other FDA-approved pharmacotherapy is limited. Topiramate is used off-label with moderate evidence. A meta-analysis of 7 trials (N=1,347) found topiramate reduced binge frequency by approximately 2.4 episodes per week compared to placebo [14]. The American Psychiatric Association guidelines note that cognitive behavioral therapy remains the first-line intervention for BED, with pharmacotherapy as an adjunct [15].

Navigating the Appeals Process

A denial is not the end. Under New York State law, Medicaid managed care members have multiple appeal levels. The first step is an internal appeal to Molina. You or your prescriber submit clinical documentation explaining why lisdexamfetamine is medically necessary and why preferred alternatives are inappropriate.

Molina must issue a decision on an internal appeal within 30 days for standard requests or 72 hours for expedited requests involving urgent clinical situations. If the internal appeal is denied, you can request an external review through the New York State Department of Financial Services (for Marketplace plans) or a fair hearing through the Office of Temporary and Disability Assistance (for Medicaid plans).

"Patients prescribed a Schedule II stimulant after failing first-line agents should not face unreasonable administrative barriers to access," per joint guidance from the American Academy of Pediatrics and the American Academy of Child and Adolescent Psychiatry [16].

Keep records of every prior authorization submission, denial letter, and appeal filing. Include your prescriber's clinical notes documenting prior medication trials, doses used, duration of each trial, and specific reasons for discontinuation. Quantified data strengthens appeals. For example, stating "Patient trialed generic amphetamine salts XR 20 mg daily for 8 weeks with documented 3 kg weight loss and persistent insomnia rated 7/10 on a sleep disturbance scale" is more effective than "Patient did not tolerate the medication."

Cost Assistance Programs

Even with coverage, some patients face cost barriers. Several resources can help.

Takeda's Vyvanse Savings Program offers eligible commercially insured patients brand Vyvanse for as low as $30 per month. This program does not apply to government-funded plans (Medicaid, Medicare, TRICARE). The program requires renewal annually [4].

For uninsured patients, Takeda's patient assistance program (Help at Hand) may provide Vyvanse at no cost to qualifying individuals with household incomes below 250% of the federal poverty level.

Generic lisdexamfetamine pricing through GoodRx, RxSaver, or Cost Plus Drugs (Mark Cuban's pharmacy) ranges from $25 to $70 for a 30-day supply without insurance, depending on dose and pharmacy. These discount programs can sometimes beat insurance copays on higher-tier medications.

Federally Qualified Health Centers (FQHCs) and 340B-eligible pharmacies can dispense medications at reduced acquisition costs. New York City has over 70 FQHCs, many of which operate on-site pharmacies [17].

Monitoring and Follow-Up After Starting Vyvanse

Once coverage is secured and the prescription is filled, proper monitoring is a clinical requirement for Schedule II stimulants. The FDA label recommends baseline and periodic assessment of heart rate, blood pressure, and weight [4]. The American Heart Association recommends a cardiovascular screening questionnaire before initiating stimulant therapy, with electrocardiography reserved for patients with positive cardiac history or symptoms [18].

Typical follow-up intervals are 2 to 4 weeks after initiation, then monthly for the first 3 months, then every 3 to 6 months once stable. At each visit, clinicians should assess ADHD symptom response using a validated scale (such as the Adult ADHD Self-Report Scale, or ASRS-v1.1), monitor for appetite changes, sleep disturbance, and mood symptoms, and confirm ongoing clinical necessity for prior authorization renewals. Most Medicaid managed care plans require annual reauthorization for stimulant medications in adults.

Lisdexamfetamine's abuse potential is lower than immediate-release dextroamphetamine because the prodrug mechanism limits the rate of active drug delivery even if the capsule contents are manipulated. A human abuse liability study (N=37) found significantly lower "drug liking" scores for lisdexamfetamine compared to equivalent doses of immediate-release dextroamphetamine when administered intravenously [19].